The Challenge of Staging Breast Cancer With PET/CT in the Era of COVID Vaccination.
Clin Nucl Med
; 46(12): 1006-1010, 2021 Dec 01.
Article
in En
| MEDLINE
| ID: mdl-33795590
ABSTRACT
ABSTRACT We report a case series of biopsy-proven reactive axillary lymph nodes, which were avid on FDG PET/CT in breast cancer patients post COVID-19 vaccination. With 4 cases presenting in a consecutive 10-day period, it became apparent that metabolically active axillary lymphadenopathy is an adverse effect of COVID-19 vaccines, currently being deployed worldwide. This may lead to patients undergoing unnecessary biopsy. We have started taking a COVID-19 vaccine status history before PET/CT. If enlarged/metabolically active axillary nodes are identified in the ipsilateral vaccinated arm, then axillary ultrasound at 4 weeks is suggested.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
COVID-19
Type of study:
Prognostic_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Clin Nucl Med
Year:
2021
Document type:
Article